Ravulizumab — Dosing in CKD & Dialysis

Ravulizumab (Complement C5 Inhibitor (monoclonal antibody)): renal dosing adjustments, dialyzability (Not expected to be removed: pharmacokinetics not clinically different in patients receiving dialysis (Ultomiris label 12.3); about 148 kDa (11). Plasma exchange, plasmapheresis and IVIg lower levels

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.